Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises the founder of Hub Planner in connection with sale to Monterro
Mandate

Vinge advises the founder of Hub Planner in connection with sale to Monterro

November 24, 2022 Employment and Benefits M&A

Vinge has advised the founder Stephen Martin in relation to the sale of a majority of the shares in Hub Planner and its software platform for resource management to the private equity firm Monterro.

Hub Planner was founded in 2013 in Stockholm by the Irishman Stephen Martin. The company’s software platform is provided as SaaS-solution and focusses on resource scheduling, vacation and time off planning as well as timesheets. Hub Planner’s current customers include companies such as Mercedes, Havas and Pfizer, but the largest customer group is consultancy firms that with the help of the platform e.g. can plan and staff projects and report hours worked.

Vinge’s team consisted of Jonas Johansson and Carl Sander (M&A) and Sara Strandberg (Employment).

 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024